| Literature DB >> 21152398 |
Feng Yang1, Katrina M Waters, John H Miller, Marina A Gritsenko, Rui Zhao, Xiuxia Du, Eric A Livesay, Samuel O Purvine, Matthew E Monroe, Yingchun Wang, David G Camp, Richard D Smith, David L Stenoien.
Abstract
BACKGROUND: High doses of ionizing radiation result in biological damage; however, the precise relationships between long-term health effects, including cancer, and low-dose exposures remain poorly understood and are currently extrapolated using high-dose exposure data. Identifying the signaling pathways and individual proteins affected at the post-translational level by radiation should shed valuable insight into the molecular mechanisms that regulate dose-dependent responses to radiation. PRINCIPALEntities:
Mesh:
Substances:
Year: 2010 PMID: 21152398 PMCID: PMC2994767 DOI: 10.1371/journal.pone.0014152
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Summary of phosphoproteomic data.
A. Venn diagram showing the distribution of phosphopeptides in sham, 2 cGy and 50 cGy treated cells. B. Quantitation of significantly altered peptides using peak intensities and spectral counting methods. C. Validation of YAP1 S127 phosphorylation by Western blotting. YAP1 S127 phosphorylation increases over time at both the lower and higher dose while CHK2 T68 phosphorylation peaks at earlier timepoints. The same samples probed with YAP1 and CHK2 antibodies showed no changes in YAP1 or CHK2 total protein at these timepoints.
Top phosphopeptides identified by peak intensities.
| Gene | Peptide | T-test: 2 cGy:C | T-test: 50 cGy:C | 2 cGy/C | 50 cGy/C | Site | PotentialKinase |
| SASH1 | R.TCS*FGGFDLTNR.S |
| ND | 24.7 | ND | S407 | AKT |
| NEXN | K.AEIKEMLAS*DDEEDVSSKVEK.A |
|
| 13.7 | 21.5 | S80 | CK II |
| C11orf58 | R.S*ASPDDDLGSSNWEAADLGNEER.K |
|
| 21.4 | 14.6 | S15 | None |
| BYSL | R.MPQDGS*DDEDEEWPTLEK.A |
|
| 21.1 | 22.6 | S98 | CK II |
| MAP1B | R.DVMS*DETNNEETESPSQEFVNITK.Y |
|
| 6.8 | 20.2 | S1144 | CK II |
| PXN | K.TGSSS*PPGGPPKPGSQLDSMLGSLQSDLNK.L |
|
| 14.4 | 14.8 | S288 | Erk1 |
| GFPT1 | R.VDS*TTCLFPVEEK.A |
|
| 14.2 | 3.5 | S243 | AMPK |
| AHSG | K.CDSSPDS*AEDVRK.V |
|
| 12.0 | 4.1 | S138 | DNA PK |
| PLEC1 | R.TS*SEDNLYLAVLR.A |
|
| 12.0 | 10.4 | S20 | PKA |
| CDC42EP1 | K.NAIS*LPQLNQAAYDSLVVGK.L |
|
| 8.4 | 11.3 | S121 | None |
| ATP2B1 | R.IEDS*EPHIPLIDDTDAEDDAPTK.R |
|
| 8.6 | 10.8 | S1193 | CK II |
| CFL1 | K.LGGS*AVISLEGKPL.- |
|
| 10.8 | 10.3 | S155 | None |
| LEO1 | K.KYVIS*DEEEEDDD.- |
|
| 6.2 | 9.6 | S658 | CK II |
| TBC1D4 | R.SLTSS*LENIFSR.G |
|
| 9.0 | 7.3 | S570 | PKC |
| SR-A1 | R.FDIYDPFHPTDEAYS*PPPAPEQK.Y |
|
| 6.3 | 8.8 | S239 | Erk1 |
| ZC3H13 | R.NTEESS*SPVRK.E |
| 0.2075 | 8.8 | 7.2 | S111 | None |
| MAP4 | K.TEVALAKDMES*PTKLDVTLAK.D |
|
| 8.6 | 6.0 | S280 | Cdk5 |
| SEPT2 | K.IYHLPDAES*DEDEDFKEQTR.L |
|
| 7.9 | 8.5 | S218 | CK II |
| ARHGEF6 | K.S*TAALEEDAQILK.V |
|
| 6.3 | 8.3 | S649 | PKC |
| ATP2B1 | R.IEDS*EPHIPLIDDTDAEDDAPTKR.N |
|
| 8.2 | 6.6 | S1193 | None |
| MATR3 | R.RDS*FDDRGPSLNPVLDYDHGSR.S |
|
| 6.1 | 8.2 | S188 | CLK2 |
| HDAC1 | R.MLPHAPGVQMQAIPEDAIPEES*GDEDEDDPDKR.I |
|
| 5.4 | 8.2 | S393 | CK II |
| PLEC1 | R.T*SSEDNLYLAVLR.A |
|
| 8.1 | 7.0 | T19 | PKA |
| ITGA4 | R.RDS*WSYINSK.S |
|
| 7.8 | 4.4 | S1027 | PKA |
| CEP170 | R.QGS*FTIEKPSPNIPIELIPHINK.Q |
|
| 2.8 | 7.7 | S838 | CAMK2G |
| USP8 | R.SYS*SPDITQAIQEEEK.R |
|
| 7.8 | 7.2 | S718 | AKT |
| EIF5B | K.WDGS*EEDEDNSK.K |
|
| 7.7 | 4.9 | S164 | CK II |
| TP53BP1 | K.MVIQGPSS*PQGEAMVTDVLEDQKEGR.S |
|
| 6.2 | 7.2 | S1114 | Erk1 |
| IFI16 | K.VSEEQTQPPS*PAGAGMSTAMGR.S |
|
| 0.15 | 0.24 | S153 | ERK1 |
| WRNIP1 | K.RPAAAAAAGSAS*PR.S | 0.1212 |
| 0.36 | 0.096 | S151 | None |
The T-test was used to identify significantly affected phosphopeptides based on relative peak intensities. The complete list can be found in supplementary Table 2.
Top phosphopeptides identified by spectral counts.
| Gene | peptide | Control | 2 cGy | 50 cGy | 2 cGY GTest | 50 cGY GTest | Site | Potential Kinase |
| PRKCDBP | APEPLGPADQSELGPEQLEAEVGES*S*DEEPVESR | 0 | 0 | 30 | ND |
| S165, S166 | CK II |
| PGRMC1 | GDQPAASGDS*DDDEPPPLPR | 16 | 0 | 2 |
|
| S56 | CK II |
| PRKAR2A | VADAKGDS*ES*EEDEDLEVPVPSR | 38 | 11 | 11 |
|
| S77, S79 | CK II |
| NOP58 | HIKEEPLS*EEEPCTSTAIASPEK | 0 | 13 | 1 |
| 0.523 | S502 | ATM |
| FAM21B | SPMFPALGEASS*DDDLFQSAK | 0 | 2 | 12 |
|
| S1092 | CK II |
| GPR124 | ALPAAAEDGS*PVFGEGPPSLK | 11 | 0 | 1 |
|
| CDK5 | |
| OSBP | MLAES*DES*GDEESVSQTDKTELQNTLR | 0 | 7 | 11 |
|
| S190, S193 | CK II |
| SSRP1 | EGMNPSYDEYADS*DEDQHDAYLER | 2 | 16 | 13 |
|
| S444 | CK II |
| RALGPS2 | CHS*LGYNFIHK | 0 | 10 | 2 |
| 1.456 | S343 | PKC |
| PLEKHA5 | TNS*MQQLEQWIK | 0 | 10 | 5 |
|
| S410 | PKA |
| SRRM1 | TRHS*PT*PQQSNR | 11 | 3 | 0 |
|
| S414, T416 | CDK5 |
| NIPBL | AITSLLGGGS*PK | 0 | 9 | 0 |
| ND | S2658 | CDK5 |
| BAZ1B | LAEDEGDS*EPEAVGQSR | 8 | 0 | 1 |
|
| S1468 | CK II |
| AHNAK | AS*LGSLEGEAEAEASSPK | 6 | 22 | 19 |
|
| S5749 | PKC |
| TJAP1 | GS*PEEELPLPAFEK | 0 | 8 | 4 |
| 3.680 | S300 | PKA |
| JUN | LQALKEEPQTVPEMPGET*PPLS*PIDMESQER | 0 | 8 | 1 |
| 0.523 | T239, S243 | GSK3 |
| MAP1A | WLAES*PVGLPPEEEDKLTR | 0 | 8 | 6 |
|
| S1776 | ERK1 |
| SORBS3 | LCDDGPQLPTS*PR | 1 | 11 | 3 |
| 0.957 | S530 | CDC2 |
| LMNA | ASSHSSQTQGGGS*VTK | 9 | 2 |
|
| S414 | PKC | |
| LARP1 | ESPRPLQLPGAEGPAIS*DGEEGGGEPGAGGGAAGAAGAGR | 7 | 0 | 5 |
|
| S90 | CK II |
| IGF2BP2 | ISYIPDEEVSSPS*PPQR | 7 | 0 | 0 |
|
| S164 | CDK5 |
| SGPP1 | NS*LTGEEGQLAR | 7 | 0 | 0 |
|
| S112 | PKA |
| IWS1 | AAVLS*DS*EDEEKASAK | 8 | 2 | 0 | 3.750 |
| S398, S400 | CK II |
| MGMT | GAGATSGS*PPAGRN | 8 | 2 | 0 | 3.750 |
| S201 | CDC2 |
| SNW1 | GPPS*PPAPVMHS*PSR | 8 | 2 | 0 | 3.750 |
| S224, S232 | ERK1, CDC2 |
| IRS2 | TYS*LTTPAR | 0 | 5 | 7 |
|
| S577 | AKT |
| AKAP12 | VLSKPPEGVVSEVEMLSS*QER | 0 | 1 | 7 | 0.520 |
| S505 | ATM |
| IRF2BP1 | AGGAS*PAASSTAQPPTQHR | 7 | 8 | 0 | 0.030 |
| S453 | none |
| PFKP | GRS*FAGNLNTYK | 7 | 6 | 0 | 0.117 |
| S386 | AKT |
| CHD3 | METEADAPS*PAPSLGER | 7 | 1 | 0 |
|
| S1660 | GSK3 |
The G-test was used to identify significantly affected phosphopeptides based on the number of observed spectra. The complete list can be found in Supplementary Table 3.
Kinases and regulators affected by radiation.
| Gene | Peptide | T-test: 2 cGy | T-test: 50 cGy | Change2 cGy | Change 50 cGy |
| ABL1 | K.GQGESDPLDHEPAVS*PLLPR.K |
|
| 2.6 | 2.9 |
| AKAP11 | R.SVS*PTFLNPSDENLK.T | 0.1771 |
| 2.7 | 2.0 |
| MAPK1 | R.VADPDHDHTGFLTEY*VATR.W |
|
| 2.8 | 2.5 |
| PDPK1 | R.ANS*FVGTAQYVSPELLTEK.S |
|
| 3.5 | 3.2 |
| PRKAB2 | R.DLSSS*PPGPYGQEMYAFR.S |
|
| 3.6 | 2.7 |
| G-Test: 2 cGy | G-Test: 50 cGy | Spectra: 0:2 cGy | Spectra: 0:50 cGy | ||
| PRKAR2A | VADAKGDS*ES*EEDEDLEVPVPSR |
|
| 38∶11 | 38∶11 |
| AKAP12 | VLSKPPEGVVSEVEMLSS*QER | 0.52 |
| 0∶1 | 0∶7 |
| AKAP2 | TNGHS*PSQPR |
|
| 11∶ 2 | 11∶ 2 |
| MAP3K11 | NVFEVGPGDS*PTFPR |
| 0.23 | 5∶0 | 5∶3 |
| MAP4K4 | RDS*PLQGSGQQNSQAGQR | 0.78 |
| 8∶5 | 8∶1 |
| PRKCDBP | APEPLGPADQSELGPEQLEAEVGES*S*DEEPVESR | 0 |
| 0∶0 | 0∶35 |
| PRKD1 | RLS*NVSLTGVSTIR | 1.28 |
| 5∶2 | 5∶0 |
| EGFR | ELVEPLT*PSGEAPNQALLR |
|
| 5∶0 | 5∶0 |
Shown is a partial list of the kinases and regulatory proteins affected by 2 and 50 cGY of radiation. The top group of peptides were identified using the peak intensity methods and T-test for quantification. The fold change for each peptide relative to control is shown. The bottom group of peptides were identified based on spectral counts using the G-test to assess significance. In both cases, those peptides showing significant change from control values are shown in bold.
Figure 2Implication of PKA signaling in radiation response.
A. Top molecular pathways affected by radiation identified by MetaCore. B. Western Blotting with PKA motif antibody demonstrates that PKA substrates are differentially phosphorylated following radiation exposure in different subcellular compartments. NHDF cells were exposed to 0 or 50 cGY of ionizing radiation and subcellular fractionation was performed 1 h post-radiation.
KEGG pathways affected by radiation.
| KEGG pathway | 2 cGy | 50 cGy | ||
| Count | Proteins | Count | Proteins | |
| Insulin signaling pathway | 8 | MAPK1, PDPK1, IRS2, EIF4EBP1, PRKAR2A, TSC1, PRKAB2, TSC2 | 6 | PDPK1, IRS2, PRKAR2A, EIF4EBP1, TSC1, PRKAB2 |
| Pathways in cancer | 7 | EGFR, MAPK1, CCDC6, HDAC1, RALBP1, JUN, ABL1 | 5 | EGFR, HDAC1, PML, LOC652671, ABL1 |
| MAPK signaling pathway | 6 | EGFR, MAPK1, JUN, RRAS, STMN1, MAP3K11 | 6 | EGFR, MAP4K4, NF1, RRAS, NFATC4, STMN1 |
| mTOR signaling pathway | 6 | EIF4B, MAPK1, PDPK1, EIF4EBP1, TSC1, TSC2 | 4 | EIF4B, PDPK1, EIF4EBP1, TSC1 |
| Tight junction | 6 | EPB41L2, RAB3B, TJP1, MAGI1, RRAS, TJAP1 | 4 | EPB41L2, MAGI1, RRAS, TJP2 |
| Adherens junction | 6 | EGFR, MAPK1, TJP1, BAIAP2, LMO7, VCL | 3 | EGFR, LMO7, CTNND1 |
| Endocytosis | 5 | EGFR, DAB2, RABEP1, SH3KBP1, IQSEC1 | 4 | EGFR, USP8, SH3KBP1, IQSEC1 |
| Spliceosome | 1 | SF3B2 | 6 | SFRS4, SFRS9, SNW1, SFRS1, PRPF38B, SF3B2 |
The DAVID web portal was used to calculate statistical enrichment of KEGG pathways.
Figure 3Biological processes affected by radiation.
Shown are the log p values for each dose group, with the dashed line indicating statistical significance (p = 0.05) identified using the DAVID web portal.
Figure 4p53 regulatory network affected by radiation exposure.
The blue dots adjacent to specific proteins indicate phosphorylation change by low dose, red dots indicate phosphorylation change by high dose, and red/blue hatched dots indicate change by both dose groups. Green edges (lines) between proteins indicate activation of the protein at the head of the arrow, and red edges indicate inactivation.